businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies

Eli Lilly and Company

Eli Lilly · 1875

Lilly didn’t just make insulin — it built the machinery that turned medicine into a regulated, prescription-gated, quality-assured industry.

Worth your time?4.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
12:05in productionCh. 1 · The Prescription Imperative/ 12:05 · ceiling 15 min
6 chapters · 12:05Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.6 chapters · 1 min read · 12:05 planned

Read the brief

Eli Lilly and Company is a foundational case in how business infrastructure — not just discovery — creates pharmaceutical power. Its early bets on quality control, prescription gatekeeping, and regulation were deliberate, profitable, and durable. The sources confirm no modern financials or valuations, so analysis must stay anchored in its documented methods and milestones.

CompaniesMedicineScientific methodVaccinesMedicine across the network →
Chapters & takeaways6
  1. 1:26
    The Prescription Imperative

    Lilly founded the company in 1876 in Indianapolis to replace ineffective patent medicines with scientifically manufactured prescription drugs.

  2. 2:52
    Manufacturing Rigour

    It staffed the first dedicated research department, invented gelatin capsules, added fruit flavourings, and sold wholesale to pharmacies — not consumers.

  3. 3:54
    Insulin as Infrastructure

    Iletin (1923) was its breakthrough: the first commercially available insulin in the US, mass-produced by Lilly — the drug that made it a global manufacturer.

  4. 5:30
    Scale Before Science

    Quinine delivered a tenfold sales increase; the firm’s success came from scalable, high-quality production — not novelty alone.

  5. 6:24
    Regulation as Strategy

    Lilly helped create the prescription system and lobbied for the 1906 law that led to the FDA — turning regulation into competitive advantage.

  6. 8:04
    Mass Production First

    It was the first to mass-produce both insulin and the Salk polio vaccine — proving its industrial capacity long before biotech existed.

3 more chaptersFewer chapters
Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • prescription system design
  • regulatory advocacy as leverage
  • industrial scaling of biologics
What does not
  • current revenue
  • valuation
  • headcount
  • market share
Study it if
  • historians of industry
  • health policy analysts
  • pharma operations strategists
Skip it if
  • investors seeking financial metrics
  • biotech founders looking for innovation playbooks
  • consumers evaluating drug access
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Eli Lilly and Company is an American multinational pharmaceutical company founded in 1876 in Indianapolis. It pioneered scientific drug manufacturing, prescription-only distribution, and federal regulation of medicines.

How it actually makes money

Lilly manufactures drugs and sells them wholesale to pharmacies. It does not sell directly to patients or rely on retail branding.

What works

Insulin — sold as Iletin from 1923 — was the most important drug in its history and did more than any other to make Lilly a major global manufacturer. Quinine sales increased tenfold. Its early commitment to high-quality, physician-restricted medicines differentiated it from patent-medicine competitors.

What does not

The sources say nothing about current revenue, margins, market share, valuation, headcount, or recent drug approvals. No claims can be made about its present-day scale, profitability, or pipeline beyond what is verified.

What to take from it

Its success came not from invention alone but from system-building: dedicated research departments, gelatin capsules, fruit flavourings, quality assurance, and lobbying for the 1906 law that created the FDA.

Is it worth your time

Yes — as a case study in how early methodical quality control, prescription gatekeeping, and regulatory advocacy shaped the modern pharmaceutical industry’s economic and ethical infrastructure.

Same desk · Companies4 of 325
10:03
Sanofi2004Sanofi is a French pharmaceutical company founded in 1973. In 2004, it merged with Aventis to form Sanofi-Aventis — a deal driven by scale, not science. It makes money from prescription drugs and vaccines, not breakthroughs. Its strength lies in manufacturing, marketing, and regulatory reach — not discovery velocity.
9:48
Serum Institute of India1966Serum Institute of India is the world's largest vaccine manufacturer by volume — a fact rooted in production capacity and multilateral procurement, not IP, pricing power, or domestic dominance. Its business model depends on high-volume, low-margin contracts with global health institutions. Nothing in the source material confirms profitability, cost structure, or innovation claims. It is infrastructure masquerading as enterprise.
10:10
LVMHBernard Arnault · 1987LVMH is a French multinational luxury goods conglomerate formed in 1987 by merger—not founded—of Louis Vuitton and Moët Hennessy. Bernard Arnault assumed control shortly thereafter, not by founding but by outmanoeuvring the initial family owners. The company operates through ~60 subsidiaries managing 75 luxury brands across six branches. Its $500B valuation in April 2023 reflects disciplined acquisition—Boussac Saint-Frères (1984), Tiffany & Co. (2021)—and structural decentralisation that preserves brand identity while centralising financial control. LVMH does not invent luxury; it acquires, integrates, and governs it.
11:48
NextEra Energy1925NextEra Energy is not a clean-tech startup. It is a century-old utility conglomerate whose dominance rests on regulatory capture, tax policy, and the strategic co-location of renewables and fossil generation—not their replacement.
Up next in Business

Elizabeth Holmes

1984 · 10:50

A company that renamed itself to avoid the word 'cure' raised $700m selling a blood test that didn’t exist.

Next brief →Back to Companies
10:50